EXOZ
eXoZymes, Inc.12.52
-1.78-12.4%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
105.01MP/E (TTM)
-Basic EPS (TTM)
-0.99Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
Updated investor presentation released
eXoZymes Inc. released an updated investor presentation on September 30, 2025, under Item 8.01, offering fresh insights into its operations and strategy. The filing attaches Exhibit 99.1 but discloses no specific financial figures or material events beyond the update itself. Investors get a snapshot of the biotech firm's direction. Details remain in the presentation.
10-Q
Q2 FY2025 results
eXoZymes posted a Q2 net loss of $2.4M, up 73.5% y/y, with operating costs climbing 91.8% to $2.5M on higher compensation and R&D amid reduced grants. For the half-year, the net loss widened to $4.2M from $2.4M y/y, driven by 71.3% higher G&A and 167.6% increased net R&D to $1.4M, while stock-based comp added $0.9M. Cash burned $2.7M in operations, leaving $7.0M on hand with no debt, yet the pre-revenue firm faces going concern doubts. No non-GAAP metrics disclosed in the 10-Q. Tariffs could hike costs and crimp grants.
AXIM
Axim Biotechnologies, Inc.
0.02+0.00
CDXS
Codexis, Inc.
1.68+0.05
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
ENTO
Entero Therapeutics Inc.
2.99+0.15
ENZN
Enzon Pharmaceuticals, Inc.
0.05+0.00
IMA
ImageneBio, Inc.
6.25+0.08
LENZ
LENZ Therapeutics, Inc.
16.70-0.38
QTZM
Quantumzyme Corp.
3.18+0.02
VIVS
VivoSim Labs, Inc.
1.99+0.01
XCUR
Exicure, Inc.
6.06+0.33